Merck KGaA to expand biologics site in Aubonne, Switzerland

Merck KGaA will invest €150 million to expand its biologics manufacturing site in Aubonne, Switzerland, adding a third building with aseptic filling lines and quality control labs. Construction is expected to be completed in 2020, with new lines operational by 2023.

“This investment reflects our commitment to ensuring that our medicines always meet the highest quality standards and are readily available to patients all over the world.”genengnews.com

• 2 sources
• genengnews.comMerck KGaA to Expand Aubonne, Switzerland Manufacturing SiteAlex PhilippidisMar 28, 2019
• bioprocessintl.comMerck to up drug product capacity by 50% at Swiss siteDan StantonApr 2, 2019

Summarized from public sources; check the original articles before acting on it.